SAN DIEGO — Eli Lilly, riding high on the success of its blockbuster weight loss drug, is now focused on sustaining its momentum amid increasing competition. With a market capitalization of approximately $685 billion, the largest in the pharmaceutical industry, Lilly is strategically advancing its pipeline while also fostering innovation through partnerships with emerging biotech companies.
Last week, the company inaugurated its latest Gateway Labs site in San Diego, part of a broader initiative that includes several incubators in the U.S. and China. These facilities are designed to provide startups with essential resources such as laboratory space, equipment, and technical expertise, thereby enhancing their chances of success in a challenging market.
In an interview with STAT, Lilly’s chief scientific officer, Daniel Skovronsky, emphasized that the launch of the new site is not merely about expanding Lilly’s own capabilities but also about strengthening the biotech ecosystem. This initiative aims to cultivate relationships with startups that could lead to future collaborations and deals, positioning Lilly as a key player in the innovation landscape.
Open the full market picture for your next decision →
